Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development
Amgen Inc
Celgene Corp
F. Hoffmann-La Roche Ltd
Numab Innovation AG
Provention Bio Inc
SYNIMMUNE GmbH
Tizia Life Sciences Plc
Tolerx, Inc. (Ictive)
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles
AMG-330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclol Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclol Antibody to Target CD3E and PSMA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blitumomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EM-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
foralumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to target CD3E and Cells Expressing NKG2D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
otelixizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasotuxizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7082859 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TACSYN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teplizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones
Featured News & Press Releases
Nov 06, 2019: Roche to present on its Non-Hodgkin Lymphoma drug candidate CD20-TCB at the American Society of Hematology 2019 Annual Meeting
Oct 24, 2019: Provention Bio announces PRV-031 (Teplizumab) granted PRIME desigtion by the European Medicines Agency
Sep 25, 2019: Amgen stops Blincyto’s Phase III paediatric ALL trials early
Sep 24, 2019: Provention Bio reiterates regulatory strategy for PRV-031 and announces completion of follow-on fincing
Sep 16, 2019: Tizia Life Sciences announces FDA approval to initiate phase I clinical trial with orally administered foralumab in healthy volunteers
Sep 10, 2019: Tizia reports phase 1 clinical data demonstrating sal treatment with foralumab was well-tolerated and produced positive trend in biomarkers of immunomodulation and anti-inflammation in healthy volunteers
Aug 20, 2019: Provention Bio announces key addition to its leadership team
Aug 05, 2019: Provention Bio announces breakthrough therapy desigtion for Teplizumab (PRV-031) for the prevention or delay of clinical type 1 diabetes in at-risk individuals
Jul 01, 2019: Tizia Life Sciences provides update on development on Foralumab
Jul 01, 2019: Independent Third Party Article in New England Jourl of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes
Jun 24, 2019: Newly published article reporting clinical activity of orally administered OKT3, a mouse anti-CD3 monoclol antibody, in moderate to severe ulcerative colitis patients, supports Tizia’s oral monoclol antibody platform
Jun 15, 2019: Amgen announces BLINCYTO (blitumomab) five-year overall survival data At EHA 2019
Jun 09, 2019: A Single course of Provention’s PRV-031 (Teplizumab) delays Type 1 Diabetes Onset in High-Risk Individuals by at least two years
Jun 02, 2019: Amgen presented data on its investigatiol drug AMG 212 at ASCO 2019
May 29, 2019: Amgen to present on its prostate cancer drug candidate AMG 212 at 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Celgene Corp, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Numab Innovation AG, H2 2019
Pipeline by Provention Bio Inc, H2 2019
Pipeline by SYNIMMUNE GmbH, H2 2019
Pipeline by Tiziana Life Sciences Plc, H2 2019
Pipeline by Tolerx, Inc. (Inactive), H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019